LRPPRC

1. LRPPRC decreases APLNR in mice (> 60% decline, p < 0.05).

   “impairs (> 60% decline; p < 0.05) the expression of genes necessary for muscle strength, including the apelin receptor Aplnr and Col6a2/6 collagens.”

   Animalselectroporation of LrpprcP27A vs LrpprcWTskeletal muscle

   Largely Distinct Post-Translational Modifications Differentiate Skeletal Muscle Wasting Caused by Cancer, Dexamethasone and Aging

   Journal of cachexia, sarcopenia and muscle·1 Feb 2026

More on APLNR

1. LRPPRC decreases type 2b myofibre size in mice (-13%, p < 0.01).

   “Moreover, LrpprcP27A reduces type 2b myofibre size (13% decline; p < 0.01) in old but not in young age.”

   Animalselectroporation of LrpprcP27A vs LrpprcWTskeletal musclemales

   Largely Distinct Post-Translational Modifications Differentiate Skeletal Muscle Wasting Caused by Cancer, Dexamethasone and Aging

   Journal of cachexia, sarcopenia and muscle·1 Feb 2026

More on Type 2b myofibre size

1. LRPPRC impairs muscle force in mice (~23%-39% in young, ~26%-36% in old, p < 0.01).

   “Electroporation of dihydroxylation-resistant LrpprcP27A (which mimics the reduction in Lrpprc dihydroxylation that occurs with atrophy) reduces muscle force in young (~23%-39%; p < 0.01) and old (~26%-36%; p < 0.01) male mice”

   Animalselectroporation of dihydroxylation-resistant LrpprcP27A vs LrpprcWTskeletal musclemales

   Largely Distinct Post-Translational Modifications Differentiate Skeletal Muscle Wasting Caused by Cancer, Dexamethasone and Aging

   Journal of cachexia, sarcopenia and muscle·1 Feb 2026

1. LRPPRC decreases frailty in silico (β = -.05 to -.13, PPH4 > 0.93).

   “LRPPRC demonstrated consistent protective effects across tissues (β = -.05 to -.13, PPH4 > 0.93)”

   In silicoblood

   From mitochondrial dysfunction to frailty and sarcopenia: genetic evidence from multi-omics data via Mendelian randomization and colocalization

   The journals of gerontology. Series A, Biological sciences and medical sciences·23 Oct 2025